EDELRIS
Created in 2005
- BETA
Up & running (A)
Existing signals show a regular activity Social networks
140 5,656Activities
Technologies
Entity types
Location
60 Av. Rockefeller, 69008 Lyon, France
Lyon
France
Employees
Scale: 51-200
Estimated: 62
SIREN
480901214Engaged corporates
7
1 7Added in Motherbase
3 years, 9 months ago
biotech Value proposition
We focus our effort to create value for your projects.
EDELRIS is a pioneering company dedicated to the design and chemical synthesis of innovative natural product-like screening Libraries, medicinal chemistry Hit-to-Lead / Lead Optimization projects, Custom Synthesis, and Affinity screening-Mass Spectrometry (AS-MS).
Aiming at the acceleration of the lead discovery and optimization process in pharma and biotech research organizations, EDELRIS uses its recognized chemistry and screening expertise in drug discovery to provide novelty to its clients and partners.
Our unique and first-in-class NP-like, easily tractable screening libraries (Fragments, Covalent binders, conventional HTS & DEL) now contain +2M in-house synthesized compounds, with built-in hit-to-lead optimization capabilities. These libraries can be reviewed by our clients on an exclusive- or non-exclusive basis.
EDELRIS has a wide range of services and provides state-of-the-art target qualification (protein and RNA), screening, and hit identification capacities by applying our in-house AS-MS (Affinity Selection – Mass Spectrometry) technologies.
We have a considerable chemical analysis department in support of our broad portfolio of ongoing organic and medicinal chemistry projects, and screening campaigns.
The EDELRIS team is capable of delivering innovative solutions to synthetic and medicinal chemistry challenges faced by our clients.
When partnering with EDELRIS, we focus our effort on creating value for your projects.
Natural Product like Compound Collections, Fragment libraries, DNA encoded libraries, Compound screening, Affinity Screening - Mass Spectrometry, Virtual Screening, Synthetic Chemistry, Organic Chemistry, Medicinal Chemistry, Analytical Chemistry, and Covalent InhibitorsOriginal language
We focus our effort to create value for your projects.
EDELRIS is a pioneering company dedicated to the design and chemical synthesis of innovative natural product-like screening Libraries, medicinal chemistry Hit-to-Lead / Lead Optimization projects, Custom Synthesis, and Affinity screening-Mass Spectrometry (AS-MS).
Aiming at the acceleration of the lead discovery and optimization process in pharma and biotech research organizations, EDELRIS uses its recognized chemistry and screening expertise in drug discovery to provide novelty to its clients and partners.
Our unique and first-in-class NP-like, easily tractable screening libraries (Fragments, Covalent binders, conventional HTS & DEL) now contain +2M in-house synthesized compounds, with built-in hit-to-lead optimization capabilities. These libraries can be reviewed by our clients on an exclusive- or non-exclusive basis.
EDELRIS has a wide range of services and provides state-of-the-art target qualification (protein and RNA), screening, and hit identification capacities by applying our in-house AS-MS (Affinity Selection – Mass Spectrometry) technologies.
We have a considerable chemical analysis department in support of our broad portfolio of ongoing organic and medicinal chemistry projects, and screening campaigns.
The EDELRIS team is capable of delivering innovative solutions to synthetic and medicinal chemistry challenges faced by our clients.
When partnering with EDELRIS, we focus our effort on creating value for your projects.
Home - Edelris
https://www.edelris.com/
| Corporate | Type | Tweets | Articles | |
|---|---|---|---|---|
 Lyonbiopôle Auvergne-Rhône-Alpes Public business cluster, Biotechnology, French Cluster, Biotechnology Research | Lyonbiopôle Auvergne-Rhône-Alpes Public business cluster, Biotechnology, French Cluster, Biotechnology Research | Other 17 Oct 2024 | | |
 Roche Pharmaceutical, Biotechnology, Biotechnology Research | Roche Pharmaceutical, Biotechnology, Biotechnology Research | Other 12 Jul 2024 | | |
 AstraZeneca Pharmaceutical, Pharmaceutical Manufacturing | AstraZeneca Pharmaceutical, Pharmaceutical Manufacturing | Other 30 Sep 2023 | | |
 Novartis Pharmaceutical, Pharmaceutical Manufacturing | Novartis Pharmaceutical, Pharmaceutical Manufacturing | Other 23 Sep 2023 | | |
 CNRS Research, Research Services | CNRS Research, Research Services | Other 8 Apr 2023 | | |
 Merck Group Pharmaceutical, Biotechnology, Pharmaceutical Manufacturing | Merck Group Pharmaceutical, Biotechnology, Pharmaceutical Manufacturing | Other 23 Sep 2023 | | |
 Pfizer Pharmaceutical, Pharmaceutical Manufacturing | Pfizer Pharmaceutical, Pharmaceutical Manufacturing | Other 4 Sep 2024 | | |